156 related articles for article (PubMed ID: 32385545)
1. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
Yoon HY; Ahn MH; Yee J; Lee N; Han JM; Gwak HS
Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
[TBL] [Abstract][Full Text] [Related]
2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
3. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
[TBL] [Abstract][Full Text] [Related]
4. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
[TBL] [Abstract][Full Text] [Related]
8. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
9. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
10. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
[TBL] [Abstract][Full Text] [Related]
11. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.
Wang P; Lin XQ; Cai WK; Xu GL; Zhou MD; Yang M; He GH
Eur J Clin Pharmacol; 2018 Apr; 74(4):433-442. PubMed ID: 29243113
[TBL] [Abstract][Full Text] [Related]
12. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
Guo Y; Hu C; He X; Qiu F; Zhao L
Drug Metab Pharmacokinet; 2012; 27(5):536-42. PubMed ID: 23099353
[TBL] [Abstract][Full Text] [Related]
13. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.
Gidal BE; Pitterle ME; Spencer NW; Maly MM
J Clin Pharm Ther; 1995 Aug; 20(4):215-9. PubMed ID: 8557785
[TBL] [Abstract][Full Text] [Related]
14. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.
Mei S; Feng W; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
Seizure; 2017 Oct; 51():22-26. PubMed ID: 28763744
[TBL] [Abstract][Full Text] [Related]
16. Effects of
Zheng XX; You YX; Zhao LL; Du Y; Xu SQ; Tang DQ
Pharmacogenomics; 2023 Feb; 24(3):153-162. PubMed ID: 36718958
[No Abstract] [Full Text] [Related]
17. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
18. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.
Chu XM; Zhang LF; Wang GJ; Zhang SN; Zhou JH; Hao HP
Eur J Clin Pharmacol; 2012 Oct; 68(10):1395-401. PubMed ID: 22476391
[TBL] [Abstract][Full Text] [Related]
19. The association of adjusted plasma valproic acid concentration with
Fang H; Wang X; Hou K; Zhang Y; Shao S; Zhang G; Feng Y; Huang L
Ann Transl Med; 2021 May; 9(10):846. PubMed ID: 34164480
[TBL] [Abstract][Full Text] [Related]
20. Effect of UGT2B7 genetic variants on serum valproic acid concentration.
Ma H; Zhang T; Gong Z; Zhou B; Zou M; Xiao S; Zhu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 38(8):766-72. PubMed ID: 23981985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]